Fred, on the 3rd of august, included in the company PR:
"The Company has an FDA approved protocol for a human abuse potential study for the intranasal route of abuse, which it plans on commencing in the coming weeks."
it looks like they could likely already be doing the HAP studies for intranasal. For sure (given their modus operandi) they are not going to tell us.
On the prospectus: they are witing for the definitive document to be approved by the SEC; in fact the "Preliminary" date 26th of May doc was withdrawn.
Now, why withdrawing it without a contextual replacement with the newly approved SEC doc I honestly don't know; it can really be anything, but it is not strictly PER SE linked to a new offering.
News 
Market Data 
Discover 
